Pharma Connect Capital has made an investment in Groningen based BiOrion, a clinical stage biopharmaceutical company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. With the investment of Pharma Connect Capital, Biorion is funded  to develop a PET-imaging diagnostic for NASH/liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for metastatic colon cancer.

← July 2018: Ir. G.J. Smidfonds participates in Pharma Connect Capital. Pharma Connect Capital invests in Philae Pharmaceuticals →